News

Why Link Between Cognition and Vision May Emerge as a Focus of Innovation

By Karen Blum | August 28, 2019

WASHINGTON – With the graying of America and a push to create age-friendly communities and health systems, ophthalmologists and innovators in the field need to…

$How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule$

How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule

By Steve Lenier | August 20, 2019

In traditional cataract surgery, the surgeon removes the clouded natural lens and replaces it with a synthetic intraocular lens (IOL), placing it into the capsular…

A Closer Look at Glaukos’ Bid for Avedro

By Keith Croes | August 14, 2019

Early market reaction to Glaukos Corp.’s all-stock acquisition of Avedro Inc. was mixed; a decrease in stock price for Glaukos and an increase for Avedro.…

OIS@ASRS Reporter’s Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

By Michelle Dalton | August 7, 2019

CHICAGO – This year’s OIS@ASRS jam-packed into one day presentations from early and late-stage retinal treatment developers, panels from key opinion leaders in industry and…

Recent Moves Show How Zeiss Is Positioning Itself for a New Era in Ophthalmology

By Steve Lenier | August 1, 2019

Carl Zeiss Meditec has made a series of strategic moves in recent weeks in glaucoma, retina, cataract, and refractive, along with reaching a milestone on…

National Vision and Eye Health Surveillance System Gears Up for September Launch

By Karen Blum | July 23, 2019

WASHINGTON – The national Vision and Eye Health Surveillance System (VEHSS) being built by researchers at the University of Chicago’s National Opinion Research Center (NORC)…

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

By Keith Croes | July 17, 2019

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting,…

OIS Index Posts Modest Gain for Q2; Ophthalmic Market Leader Alcon Joins Index

By Michael Lachman | July 10, 2019

The OIS Index of ophthalmic stocks posted a modest positive return of +0.8% during the second quarter of 2019. The index outperformed the NASDAQ Biotechnology…

A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

By Keith Croes | June 26, 2019

NEW YORK – In what’s been called “a transformative move for both companies,” AbbVie has agreed to buy Allergan in a deal valued at $63…

After Re-submitted NDA a Year Ago, Ocular Therapeutix Finds Its Path Forward

By Steve Lenier | June 19, 2019

In July 2018 Ocular Therapeutix re-submitted its New Drug Application for Dextenza to the Food and Drug Administration. At that time, Scott Corning, the company’s…